FDA opens post-market review of BHA

The US Food and Drug Administration has launched a comprehensive reassessment of butylated hydroxyanisole (BHA), expanding scrutiny of a long-established additive that remains in the formulation toolkit for fats, oils, and shelf-stable products.

In its announcement, the FDA said the review “will consider whether BHA is safe under its current conditions of use in food and as a food contact substance.” That scope matters for manufacturers that encounter BHA both as an ingredient and as a component used in packaging-related applications, where migration and exposure questions can become central to a risk assessment.

BHA sits in an awkward regulatory position: familiar, widely understood by formulators, and legally embedded in the modern packaged-food system, yet dogged by toxicology concerns that have not gone away. The agency noted that BHA has been in the food supply for decades and referenced the National Toxicology Program’s long-standing classification of BHA as “reasonably anticipated to be a human carcinogen,” based on animal studies. The FDA also pointed to label data suggesting use has declined in recent years, while still appearing across categories including frozen meals, breakfast cereals, cookies, candy, ice cream, and meat products, including products marketed to children.

Practically, a post-market reassessment forces a different level of homework from both ingredient suppliers and finished-goods manufacturers. The FDA has issued a Request for Information, seeking updated data on current use patterns and safety, which will inevitably bring attention to real-world inclusion rates, category-by-category exposure, and where BHA still turns up in legacy recipes that have not been materially changed in years.

For food manufacturers, the operational risk is less about a sudden “ban tomorrow” scenario and more about the planning horizon that opens up when an additive moves onto a named priority list. If BHA’s acceptable conditions of use are tightened, manufacturers could be looking at reformulation projects that run beyond R&D and into procurement, line trials, shelf-life validation, and packaging compatibility work. Even when technical substitutes exist, replacing an antioxidant that stabilises fats and oils can shift flavour stability, oxidation profiles, and storage performance, which has knock-on implications for distribution, waste, and customer complaints.

The review also lands in a period where additive governance is becoming more visible, rather than sitting quietly behind historical approvals and internal “GRAS” decisions. FDA Commissioner Marty Makary said, “We are taking decisive action to ensure that chemicals in our food supply are not causing harm,” and flagged that similar assessments are expected to follow for other chemicals, including BHT and azodicarbonamide. For ingredient and packaging suppliers, that reads as a cue to get data packages, specifications, and traceability documentation ready before customers start asking.

For brands, the smartest move is often unglamorous: map where BHA is present, at what levels, and in which SKUs, then pressure-test the cost and lead-time of alternatives before the supply chain is forced into a reactive switch.